Board Intentions to apply for long-term fund-raising plan
1.Date of the board of directors resolution:2016/05/13 2.Source of capital increase funds:The intention to issue not more than 20 million ordinary shares in domestic cash fundraising or a capital increase …
Supplementary notice on a company board resolution for the upcoming 2016 Annual Shareholders’ Meeting
1.Date of the board of directors resolution:2016/05/13 2.Date for convening the shareholders’ meeting:2016/06/27 3.Location for convening the shareholders’ meeting: Masterlink Securities Education and Training Center (Da-an District, Taipei Dun Hua …
Company Position Statement Regarding Recent Investigation of Senior Executives
OBI Pharma strongly denies allegations of insider trading. Since March 2016, the Shi-Lin District Prosecutor’s Office has been investigating whether senior OBI executives sold shares with foreknowledge of the results …
Company reports outsider suspected of “rumor mongering” intended to manipulate company’s stock, and plans to take legal action against “NEXT Magazine”
1.Parties to the legal matter, name of the court, disposing agency, and reference/case numbers of relevant documents: Plaintiff: OBI Pharma, Inc. Defendants: (1)An individual spreading false rumors and manipulating company …
OBI Pharma announces the end of the implementation for its first treasury share buyback program
1.Originally determined ceiling on total monetary amount of the share repurchase:NTD 5,646,671,868 2.Original scheduled period for the repurchase:2016/02/25-2016/04/24 3.Originally determined number of shares to be repurchased:3,000 shares 4.Originally determined type …
OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting
OBI Pharma, Inc. today announced that the American Society of Clinical Oncology (ASCO) has formally accepted its abstract regarding the results of its Phase 2/3 study of OBI-822/821 (formerly OPT‐822/OPT‐821), …
OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer
Plans to Advance to Global Phase 3 Clinical Program TAIPEI, TAIWAN, February 21, 2016 — OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced the topline results of …
OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan
OBI Eligible to Receive Milestone Payments as well as US$3.0 Million Upfront Cash Payment and Royalties on Sales in Taiwan. DIFICID was approved in 2012 by Taiwan’s Department of Health …
OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016
TAIPEI, TAIWAN, August 31/ — OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), announced it plans to unblind its flagship OBI-822/821 (formerly OPT‐822/OPT‐821) Phase 2/3 clinical trial (Protocol Number …
Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015
There has been a lot of discussion about the Progressive Disease (PD) number reported in an erroneous slide deck that was inadvertently uploaded on Monday, 25 May 2015, to the …